Nouscom
Basel
About Nouscom
Nouscom is a developer of an immunotherapy platform that aims to create modified viral vector vaccines for cancer treatment. The company's platform makes use of a portfolio of engineered viral vectors that have been optimized for the efficient expression of long strings of tumor neoantigens. It also includes a toolkit for inducing broad and potent antitumor T-cell responses, allowing patients to boost cancer-specific cellular immunity.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $143.4M
- Funding stage: Late Stage Venture
- Last round: Series C (Mar 2024)
- Website: nouscom.com
- Phone: +41 612-01-18-31
Industries & Categories
Biotechnology, Genetics, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/nouscom-17304 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.